首页 | 本学科首页   官方微博 | 高级检索  
检索        

2014-2018年南京市第二医院门诊药房水飞蓟类保肝药物的使用情况分析
引用本文:沈洁,束艳,童宁,张小玉.2014-2018年南京市第二医院门诊药房水飞蓟类保肝药物的使用情况分析[J].现代药物与临床,2019,34(11):3433-3436.
作者姓名:沈洁  束艳  童宁  张小玉
作者单位:南京中医药大学附属南京医院(南京市第二医院)药学部,江苏 南京,210003;南京中医药大学附属南京医院(南京市第二医院)药学部,江苏 南京,210003;南京中医药大学附属南京医院(南京市第二医院)药学部,江苏 南京,210003;南京中医药大学附属南京医院(南京市第二医院)药学部,江苏 南京,210003
摘    要:目的了解南京市第二医院门诊药房2014—2018年水飞蓟类保肝药物的门诊使用情况,分析该类药物的使用特点和趋势,为临床合理用药和科学管理提供参考。方法收集南京市第二医院2014—2018年水飞蓟类药物的门诊使用资料,对消耗量、销售金额、用药频度(DDDs)、日均费用(DDC)等进行整理分析。结果 2014—2018年,水飞蓟类保肝药物中年消耗量最高的是水飞蓟宾葡甲胺,但从2016年开始逐年降低,至2018年仍占48.75%;销售金额和DDDs值排名最高的是水飞蓟素,其从2015年开始逐年上升,至2018年销售金额占37.88%;5年内益肝灵液体胶囊的DDC值一直最高,其日治疗费用达到8.12;复方益肝灵的消耗量、销售金额、DDDs和DDC均处于最低值,其2018年的消耗量占比仅为0.21%。结论南京市第二医院门诊治疗肝炎以纯度较高和价格适中的水飞蓟宾、水飞蓟素以及水飞蓟宾葡甲胺这3种药物为主,这与其适宜的价格和适宜的用药频度是一致的。

关 键 词:水飞蓟类保肝药物  销售金额  用药频度  日均费用
收稿时间:2019/4/16 0:00:00

Analysis on usage of Silybum marianum liver-protecting drugs in Department of Outpatient in The Second Hospital of Nanjing from 2014 to 2018
SHEN Jie,SHU Yan,TONG Ning and ZHANG Xiao-yu.Analysis on usage of Silybum marianum liver-protecting drugs in Department of Outpatient in The Second Hospital of Nanjing from 2014 to 2018[J].Drugs & Clinic,2019,34(11):3433-3436.
Authors:SHEN Jie  SHU Yan  TONG Ning and ZHANG Xiao-yu
Institution:Department of Pharmacy, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing 210003, China,Department of Pharmacy, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing 210003, China,Department of Pharmacy, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing 210003, China and Department of Pharmacy, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing 210003, China
Abstract:Objective To investigate the utilization condition of Silybum marianum liver-protecting drugs in Department of Outpatient in The Second Hospital of Nanjing from 2014 to 2018, and the characteristics and tendency were analyzed so as to provide references for the rational use and scientific management of the drugs. Methods The consumption data about Silybum marianum liver-protecting drugs in Department of Outpatient in The Second Hospital of Nanjing from 2014 to 2018 were collected for analysis of consumption sum, sales amount, DDDs, and DDC etc. Results From 2014 to 2018, consumption sum of silybin meglumine accounted for the largest proportion in Silybum marianum liver-protecting drugs, and decreasing year by year from 2016, accounted for 48.75% in 2018. The sale amount and DDDs of silymarin accounted for the largest proportion, and increasing year by year from 2015, accounted for 37.88% in 2018. DDC value of Yiganling Liquid Capsules in five years has been the highest, and its daily treatment cost has reached 8.12. Consumption, sales amount, DDDs, and DDC of Compound Yiganling were at the lowest level, and its consumption in 2018 was only 0.21%. Conclusion Silibinin, silymarin and silibinin meglumine with high purity and moderate price is mainly used in Department of Outpatient in The Second Hospital of Nanjing, which is consistent to its appropriate price and appropriate frequency of medication.
Keywords:Silybum marianum liver-protecting drugs  sale amount  DDDs  DDC
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号